Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Trevena, Inc. TRVN

Healthcare  —  Biotechnology
0.01 0.00 0.00% as of 25 Sep
Market cap
$1.8M
P/E
0.0×
Cash Flow Champion (3y) Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Trevena, Inc. (TRVN) Business Profile

Updated before January 2025

Company Overview

Trevena, Inc. (NASDAQ: TRVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with central nervous system (CNS) disorders. Founded in 2007 and headquartered in Chesterbrook, Pennsylvania, Trevena was established by a team of scientists and entrepreneurs with a vision to redefine the treatment landscape for CNS conditions. The company leverages its proprietary platform to develop novel drugs that target G-protein coupled receptors (GPCRs), a class of proteins that play a critical role in cellular communication and are implicated in numerous diseases.

Trevena’s leadership team comprises seasoned professionals with extensive experience in the pharmaceutical and biotechnology industries. The company is led by Carrie L. Bourdow, who serves as President and Chief Executive Officer. Under her leadership, Trevena has focused on advancing its pipeline of innovative therapies and achieving key regulatory milestones. The company’s board of directors includes experts in drug development, commercialization, and corporate strategy, further strengthening its position in the biopharmaceutical sector.

Core Business Segments

Trevena’s core business revolves around the development of novel therapies for CNS disorders. The company’s product portfolio is categorized into the following segments:

1. Pain Management

Trevena’s flagship product in this category is Olinvyk® (oliceridine), an opioid receptor agonist approved by the U.S. Food and Drug Administration (FDA) for the management of acute pain in adults. Olinvyk is designed to provide effective pain relief while minimizing the risk of adverse effects commonly associated with traditional opioids, such as respiratory depression and gastrointestinal issues. This product represents a significant advancement in pain management, particularly for patients requiring short-term intravenous opioid therapy.

2. CNS Disorders Pipeline

Trevena is actively developing a pipeline of drug candidates targeting various CNS disorders. Key products in this segment include:

  • TRV027: A novel angiotensin II type 1 receptor (AT1R) selective agonist being developed for the treatment of acute respiratory distress syndrome (ARDS) and other cardiovascular conditions.
  • TRV045: A selective sphingosine-1-phosphate receptor modulator in preclinical development for the treatment of epilepsy and other CNS disorders.

3. Research and Development (R&D)

Trevena invests heavily in R&D to discover and develop new therapies that address unmet medical needs. The company’s proprietary GPCR platform enables the identification of drug candidates with improved efficacy and safety profiles, positioning Trevena as a leader in the field of CNS drug development.

Business Model

Trevena’s business model is centered on the development and commercialization of innovative therapies for CNS disorders. The company generates revenue through product sales, licensing agreements, and strategic partnerships. Key elements of Trevena’s business model include:

  • Product Commercialization: Trevena markets Olinvyk in the United States and collaborates with international partners to expand its global reach.
  • Strategic Partnerships: The company collaborates with pharmaceutical and biotechnology companies to advance its pipeline and bring new therapies to market. These partnerships provide access to additional resources and expertise, accelerating the development process.
  • Licensing Agreements: Trevena licenses its proprietary technologies and drug candidates to third parties, generating revenue through upfront payments, milestone payments, and royalties.

Strategic Direction

Trevena is committed to advancing its mission of improving patient outcomes through innovative therapies. The company’s strategic priorities include:

  • Pipeline Expansion: Trevena aims to expand its pipeline by advancing existing drug candidates and exploring new therapeutic areas. The company is particularly focused on addressing unmet medical needs in CNS disorders and pain management.
  • Global Market Expansion: Trevena is working to establish partnerships and secure regulatory approvals to bring its products to international markets.
  • Sustainability Goals: The company is dedicated to promoting sustainability in its operations and ensuring the ethical development of its therapies.
  • Innovation: Trevena continues to invest in its proprietary GPCR platform to discover and develop next-generation therapies with improved safety and efficacy profiles.

Competitive Landscape

Trevena operates in a highly competitive biopharmaceutical industry, facing competition from both established pharmaceutical companies and emerging biotechnology firms. Key competitors include:

  • Eli Lilly and Company: A global leader in CNS drug development with a strong portfolio of therapies for pain and neurological disorders.
  • Pfizer Inc.: A major player in the pain management market, offering a range of opioid and non-opioid analgesics.
  • Biogen Inc.: A biotechnology company specializing in therapies for neurological and neurodegenerative diseases.
  • Amgen Inc.: A leading biopharmaceutical company with a focus on innovative therapies for CNS disorders and pain management.

Trevena differentiates itself through its proprietary GPCR platform and focus on developing therapies with improved safety and efficacy profiles.

Risk Factors

Trevena faces several risks that could impact its business operations and financial performance, including:

  • Market Dependence: The company’s revenue is heavily dependent on the success of Olinvyk and its pipeline products. Any setbacks in commercialization or regulatory approval could adversely affect its financial performance.
  • Regulatory Risks: The biopharmaceutical industry is subject to stringent regulatory requirements. Delays or failures in obtaining regulatory approvals could hinder Trevena’s ability to bring new products to market.
  • Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers for the production of its therapies. Any disruptions in the supply chain could impact product availability and sales.
  • Competition: Intense competition from established pharmaceutical companies and emerging biotechnology firms poses a significant challenge to Trevena’s market position.

Recent Developments

Trevena has made significant progress in advancing its pipeline and achieving key milestones. Recent developments include:

  • Olinvyk Commercialization: The company has expanded the availability of Olinvyk in the United States and is pursuing regulatory approvals in international markets.
  • Pipeline Advancements: Trevena has initiated clinical trials for TRV027 and TRV045, demonstrating its commitment to addressing unmet medical needs in CNS disorders.
  • Strategic Partnerships: The company has entered into collaborations with leading pharmaceutical companies to accelerate the development and commercialization of its therapies.
  • COVID-19 Impact: Trevena has adapted its operations to address challenges posed by the COVID-19 pandemic, ensuring the continuity of its R&D activities and supply chain.

Investment Considerations

Investors considering Trevena as a potential investment should weigh the following strengths and risks:

Strengths

  • Innovative product portfolio targeting CNS disorders and pain management.
  • Proprietary GPCR platform enabling the development of next-generation therapies.
  • Strong leadership team with extensive industry experience.
  • Strategic partnerships and licensing agreements providing additional revenue streams.

Risks

  • Dependence on the success of Olinvyk and pipeline products.
  • Regulatory and competitive challenges in the biopharmaceutical industry.
  • Potential supply chain disruptions impacting product availability.
  • High R&D expenses and the inherent risks of drug development.

Conclusion

Trevena, Inc. is a pioneering biopharmaceutical company with a strong focus on developing innovative therapies for CNS disorders and pain management. With its proprietary GPCR platform, robust pipeline, and strategic partnerships, Trevena is well-positioned to address unmet medical needs and drive future growth. While the company faces challenges such as regulatory risks and intense competition, its commitment to innovation and patient-centric solutions underscores its potential for long-term success in the biopharmaceutical industry.